Thursday, 15 October 2026European Markets

VERALLIA And 2 Other Stocks Have Very High Payout Ratio

Loading stream...

(vianews) - sergeferrari group (sefer.pa), verallia (vrla.pa), bassac (bass.pa) are the highest payout ratio stocks on this list.

we have gathered information concerning stocks with the highest payout ratio as yet. the payout ratio in itself isn't a guarantee of good investment but it's an indicator of whether dividends are being paid and how the company chooses to distribute them.

when investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.

1. sergeferrari group (sefer.pa)

100% payout ratio

sergeferrari group sa designs, develops, manufactures, and markets composite materials for lightweight architectural and outdoor applications in france and internationally. it provides its products for solar protection, tensile architecture, modular structures, and furniture/marine markets. the company offers solutions for indoor and outdoor blind, and terrace blind and awning; tensile roof and shading structure; indoor and outdoor acoustic treatment; bioclimatic façade, including building construction and renovation; and waterproof breathable membrane applications. it also provides products and solutions for modular structure, visual communication for printed advertisement, protection, environment, and yachting applications. in addition, the company offers outdoor sling seats and membranes for garden furniture; and upholstery for indoor and outdoor furniture. the company was founded in 1973 and is headquartered in saint-jean-de-soudain, france.

earnings per share

as for profitability, sergeferrari group has a trailing twelve months eps of €0.88.

pe ratio

sergeferrari group has a trailing twelve months price to earnings ratio of 6.65. meaning, the purchaser of the share is investing €6.65 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.7%.

moving average

sergeferrari group's value is below its 50-day moving average of €6.04 and way under its 200-day moving average of €6.51.

more news about sergeferrari group.

2. verallia (vrla.pa)

88.84% payout ratio

verallia société anonyme manufactures and sells glass packaging products for beverages and food products worldwide. it provides bottles for still and sparkling wines, spirits, beers, soft drinks, and oils. the company offers jars for baby food, dairy products, jams, honey, spreads, condiments, sauces, and preserves. verallia société anonyme was founded in 1827 and is based in courbevoie, france.

earnings per share

as for profitability, verallia has a trailing twelve months eps of €4.01.

pe ratio

verallia has a trailing twelve months price to earnings ratio of 8.99. meaning, the purchaser of the share is investing €8.99 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 29.81%.

more news about verallia.

3. bassac (bass.pa)

43.03% payout ratio

bassac société anonyme operates as a real estate development company primarily in france, belgium, germany, and spain. it offers residential buildings and houses, and commercial real estate, as well as prefabricated garages and land. the company was incorporated in 1972 and is headquartered in boulogne-billancourt, france. as of december 31, 2021, bassac société anonyme operates as a subsidiary of premier investissement sas.

earnings per share

as for profitability, bassac has a trailing twelve months eps of €5.81.

pe ratio

bassac has a trailing twelve months price to earnings ratio of 7.16. meaning, the purchaser of the share is investing €7.16 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.26%.

moving average

bassac's value is under its 50-day moving average of €42.50 and under its 200-day moving average of €44.60.

revenue growth

year-on-year quarterly revenue growth grew by 1.1%, now sitting on 1.3b for the twelve trailing months.

dividend yield

as stated by morningstar, inc., the next dividend payment is on may 21, 2024, the estimated forward annual dividend rate is 1.5 and the estimated forward annual dividend yield is 3.5%.

volume

today's last reported volume for bassac is 1487 which is 96.43% above its average volume of 757.

more news about bassac.

1. 1 (1)

1% payout ratio

1

earnings per share

as for profitability, 1 has a trailing twelve months eps of €1.

pe ratio

1 has a trailing twelve months price to earnings ratio of 1. meaning, the purchaser of the share is investing €1 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1%.

volume

today's last reported volume for 1 is 1 which is 1% above its average volume of 1.

more news about 1.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com